Vioxx - A Solution for Alzheimer’s Disease?
Alzheimer’s is a clinical study that is part of the University of Pennsylvania’s Alzheimer’s Disease Center to determine whether NSAIDs, in particular COX-2 selective inhibitors, will reduce the risk of developing Alzheimer’s disease similar to the NSAID Indomethacin. Started in February 1999 there have been two presentations from their collected data on June of 2002 and 2003. Vioxx, Bextra and Celebrex are all COX-2 selective inhibitors. Data is still currently being collected for this study.
If you or a loved one has suffered due to a side effect of Vioxx, you can fill out this simple form for a free case review within 24 hours.
Weitz & Luxenberg is no longer accepting Vioxx cases.
see also:
VIGOR
Might Vioxx affect your GI tract? Find answers from the VIGOR studyVIGOR - Merck's Clinical Trial determining Vioxx's affect on the GI
Alzheimer's Disease
Affected by Alzheimer’s Disease? Vioxx has been tested to helpWhat you should know about Alzheimer's Disease and Vioxx testing
Vioxx Clinical Trials
Want some history? See the Vioxx Clinical Trials & FDA Studies chartWhat you need to know about Vioxx - Clinical Trials & FDA Studies
